Association of serum b-cell activating factor level and proportion of memory and transitional b cells with clinical response after rituximab treatment of bullous pemphigoid patients

Journal of Investigative Dermatology

Volumn 133, Issue 12, 2013, Pages 2786-2788

  Hall, Russell P ^a   Streilein, Robert D ^a   Hannah, Deborah L ^a   McNair, Patrice D ^a   Fairley, Janet A ^b   Ronaghy, Arash ^a   Edhegard, Kim D ^a   Levesque, Marc C ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; PREDNISONE; RITUXIMAB;

BULLOUS PEMPHIGOID; CLINICAL ARTICLE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; LETTER; MALE; MEMORY CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL;

EID: 84887822290     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2013.236     Document Type: Letter

References (13)

1. Joly P, Baricault S, Sparsa A et al. (2012) Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol 132:1998-2004
2. Joly P, Mouquet H, Roujeau JC et al. (2007) A single cycle of rituximab for the treatment of severe pemphigus. N Engl JMed 357:545-52
3. Kreuzaler M, Rauch M, Salzer U et al. (2012) Soluble BAFF levels inversely correlate with peripheral B cell numbers and the expression of BAFF receptors. J Immunol 188:497-503
4. Lavie F, Miceli-Richard C, Ittah M et al. (2007) Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 66:700-2
5. Leandro MR, Cambridge G, Ehrenstein MR et al. (2006) Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 54:613-20
6. Levesque MC, Moody MA, Hwang KK et al. (2009) Cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 6:e1000107
7. Messingham K, Noe M, Chapman M et al. (2009) A novel ELISA reveals high frequencies of BP 180-specific IgE production in bullous pemphigoid. J Immunol Meth 346:18-25
8. Mouquet H, Musette P, Gougeon ML et al. (2008) B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 128:2859-69
9. Nagel A, Podstawa E, Eickmann M et al. (2009) Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 129:2202-10
10. Roll P, Dorner T, Tony HP (2008) Anti-CD20 therapy in patints with rheumatoid arthritis predictors of response and B cell subset regeneration after repeated treatments Arthritis Rheum 58:1566-75
11. Roujeau JC, Lok C, Bastuji-Garin S et al. (1998) High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 134:465-9
12. Sellam J, Rouanet Sp, Hendel-Chavez H et al. (2011) Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum 63:3692-701
13. Tony HP, Burmester G, Schulze-Koops H et al. (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13:R75